- Design
- Prospective family cohort (SAFEHEART), median 12.4 years
- Population
- 348 children with heterozygous FH, 165 unaffected siblings, 288 affected parents
- Primary outcome
- LDL-C burden and cardiovascular events
- Effect
- Events by age 39: 0.3% treated children vs 5.2% parents; LDL burden about 5,900 vs 10,200 mg/dL-years
SAFEHEART is a Spanish prospective cohort of families with genetically confirmed heterozygous familial hypercholesterolaemia. It followed 348 affected children, 165 unaffected siblings and 288 affected parents for a median 12.4 years.
Affected children started lipid-lowering at a median 14.5 years, against 36.1 years in their parents. On treatment, the children's LDL-C fell 47% to 3.0 mmol/L, close to their unaffected siblings' 2.7 mmol/L. By age 30–40 their cumulative LDL burden was about 5,900 mg/dL-years against about 10,200 in their parents. By age 39, cardiovascular events had occurred in 0.3% of treated children, 5.2% of parents and none of the unaffected siblings.
This is observational and compares generations, so differences in era and care also play a part. But the direction is consistent with the cumulative-exposure model of atherosclerosis, and the absolute gap is large. It strengthens the case for finding FH in childhood, usually through cascade testing from an affected parent, and starting treatment in adolescence as guidelines already allow.
In India, where FH is underdiagnosed and paediatric lipid testing is uncommon, the practical step is to test the children of every adult diagnosed with FH.
- Test the children of every adult with familial hypercholesterolaemia, ideally before adolescence.
- Consider statin therapy from about age 10 in children with confirmed FH, as guidelines allow.
- Treated children reached LDL levels close to unaffected siblings, about 3.0 versus 2.7 mmol/L.
- Explain to parents that early treatment lowers lifetime cholesterol exposure, which drives risk.
- Refer children with very high LDL or a homozygous picture to a specialist lipid clinic.
Why it matters
It moves FH from an adult cardiology problem to a paediatric diagnosis where the benefit is largest.
Don't overread it
This compares children with their parents in a cohort, not randomised groups, so era and care differences also contribute.
The statistics, in plain English
The event rates are absolute percentages by age 39: 0.3% versus 5.2%. They are crude comparisons between generations, not adjusted effect estimates, so they show the size of the gap rather than prove treatment caused all of it.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for cardiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free